Previous 10 | Next 10 |
Phase 1b/2 Study Evaluating DAY101 in Combination with Pimasertib, Day One’s MEK Inhibitor, Expected to Begin in First Quarter of 2022 SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical ...
Day One Biopharmaceuticals (NASDAQ:DAWN): Q3 GAAP EPS of -$0.33 misses by $0.07. Cash and cash equivalents and short-term investments totaled $297.2M at September 30, 2021. Press Release For further details see: Day One Biopharmaceuticals EPS misses by $0.07
Enrollment Progresses in the Pivotal Phase 2 FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG; Initial Data Expected in 1H 2022 Upcoming CTOS Meeting to Highlight Single Agent Activity of Lead Drug Candidate, DAY101, in Spindle Cell Carcinoma Compassionate Use Case ...
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced an u...
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically-defined cancers, today announced the...
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the ...
DAY101 Granted Rare Pediatric Disease Designation from FDA DAY101 Granted Orphan Designation from European Commission Dosed the First Patients in Pivotal FIREFLY-1 Clinical Trial of DAY101 in Patients with pLGG Successfully Completed $184 Million Upsized Initial ...
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that...
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced that...
naphtalina/iStock via Getty Images Day One Biopharmaceuticals ([[DAWN]] +1.8%) has lost ~16.0% in value since its public debut in late May. Today as its IPO quiet period draws to a close, the clinical-stage biopharma company has attracted a range of bullish recommendations from Wall Street. T...
News, Short Squeeze, Breakout and More Instantly...
Day One Biopharmaceuticals Inc. Company Name:
DAWN Stock Symbol:
NASDAQ Market:
Day One Biopharmaceuticals Inc. Website:
2024-07-20 21:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-10 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 09:30:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for DAWN on July 8, 2024 07:54AM ET. The previous analyst recommendation was Overweight. DAWN was trading at $13.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...